Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

Maart 27, 2025
PERSBERICHT NIET-GEREGLEMENTEERDE INFORMATIE 27 maart 2025, 07:00 am CET Gent, België – 27 maart 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, de “Vennootschap” of “Sequana Medical”), een pionier in de behandeling van vochtoverbelasting in leveraandoeningen, hartfalen en kanker, kondigt met genoegen haar deelname aan de “VFB Happening 2025” aanstaande zaterdag, 29 maart 2025, in...
Read More

PERSBERICHTEN

INSCHRIJVEN OP ONZE PERSBERICHTEN